Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers Aug 7, 2018 Life Science
Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China Aug 1, 2018 Life Science
HiFiBiO Therapeutics Signs Multi-Target Antibody Discovery Agreement with Takeda Jul 31, 2018 Life Science
Laekna Acquires Exclusive Worldwide Rights to Two Clinical Stage Oncology Assets Jul 31, 2018 Life Science
